Ionis Pharmaceuticals INC 10-Q quarterly reports

Ionis Pharmaceuticals reports a net loss for Q2 2026, with revenue impacted by significant upfront payments in the prior year, while commercial revenue shows growth driven by new product sales.

Ionis Pharmaceuticals reported a significant increase in revenue for the first quarter of 2026, driven by strong commercial product sales and milestone payments, though the company still posted a net loss.

Ionis Pharmaceuticals reports significantly increased revenue and narrowed net loss in Q3 2025, driven by new product launches and strategic collaborations.

Ionis Pharmaceuticals reported a significant surge in second-quarter revenue and a return to quarterly net income, driven by new product launches and a major collaboration deal, while advancing its robust RNA-targeted therapeutic pipeline.

Ionis Pharmaceuticals announces its Q1 2025 financial results, showcasing commercial growth driven by TRYNGOLZA and WAINUA, and advancements in its neurology, cardiology, and high patient need pipeline.

Ionis Pharmaceuticals' Q3 2024 results show a net loss, but also highlight revenue from new commercial products and advancements in their drug pipeline.

Ionis Pharmaceuticals reported a strong second quarter driven by the successful launch of WAINUA and significant progress across its late-stage pipeline.

Ionis Pharmaceuticals reported a net loss of $142.8 million for the first quarter of 2024, with revenue impacted by timing of SPINRAZA shipments but bolstered by the launch of WAINUA.